MnDPDP: Contrast Agent for Imaging and Protection of Viable Tissue

Table 1

Therapy with MnDPDP: cardioprotective adjunct to pPCI during AMI [25].

Group	Ischemia time (min)	TIMI flow grade I before reflow (patients)	STER (%)	CK-MB (μg/L)	LVEF (%)	Infarct size (%)	LV thrombi (patients)
Placebo (n = 10)	144	3 of 10	73.1	4850	41.8	32.5	5 of 8
MnDPDP (n = 10)	206	0 of 10	84.3	4730	47.7	26.2	1 of 10
value	0.04	0.07	0.08	0.75	0.50	0.62	0.02

Data are expressed as mean with values (two-tailed) included. Data in three rows to the right were obtained by the use of late Gd-enhancement MRI (gadopentetate dimeglumine). TIMI, grading of coronary flow from 0 to 3; STER, ST segment elevation regression at 48 hours; CK-MB, plasma creatine kinase isoenzyme MB 0–48 hours; LVEF: LV ejection fraction.